Carbonic Anhydrase-IX Is a Specific and Sensitive Theragnostic Target for Imaging and Radioimmunotherapy in Metastatic Colorectal Cancer.

ABSTRACT:

Background and aims

Over 40% of colorectal cancer (CRC) patients develop metastatic disease. Their survival outlook is very low, highlighting the urgent need to improve the detection and therapeutic management of metastatic colorectal cancer (mCRC), particularly when metastases are not surgically resectable. Our study aimed to characterize the preclinical utility of targeting carbonic anhydrase IX (CA-IX) for metastasis imaging and for therapeutic purposes in patients with CRC liver metastases.

Methods

CA-IX expression was characterized in 46 liver metastasis samples using RNA sequencing and immunohistochemical staining. We labeled girentuximab, a clinical grade CA-IX antibody, with zirconium-89 ([⁸⁹Zr]Zr) or lutetium-177 ([¹⁷⁷Lu]Lu), and characterized

SUBMITTER: Swaroop D 

PROVIDER: S-EPMC12860988 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature